Castle Biosciences CSTL Business Segments — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — interest expense, nonoperating?
- Castle Biosciences (CSTL) reported business segments — interest expense, nonoperating of $134K in Q1 2026.
- How has Castle Biosciences's business segments — interest expense, nonoperating changed year-over-year?
- Castle Biosciences's business segments — interest expense, nonoperating increased by 688.2% year-over-year, from $17K to $134K.
- What is the long-term trend for Castle Biosciences's business segments — interest expense, nonoperating?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — interest expense, nonoperating has grown at a 71.7% compound annual growth rate (CAGR), from $17K to $86K.
- What does business segments — interest expense, nonoperating mean?
- Captures the costs associated with servicing debt or other financial obligations that are not directly tied to core operating activities. This metric is used to assess the financial leverage and the cost of capital for the segment.